Sentinel – Just Do It
Executive Summary
As FDA refines an approach to its Sentinel post-market drug safety surveillance project, "we will address issues of patient privacy and confidentiality [and] we will address the issues of the scientific accuracy and reliability of the data before we use it," Commissioner Andrew von Eschenbach says at a June 13 Brookings Institution conference on the issue. "On the other hand, in terms of implementing it, if we can identify the fatal flaws and address them, we should do that and must do that before we do it. But if it isn't a fatal flaw, it's just a flaw, a blemish, or a defect, it shouldn't stop us from doing it. It may impair us or prevent us from using it, but that's an important distinction." Sentinel is envisioned as a national network of electronic data systems that FDA could access to monitor the safety of drugs and medical devices (1"The Pink Sheet," May 26, 2008, p. 3)
You may also be interested in...
FDA’s Sentinel Program Readies For Patrol As Stakeholders Watch For Details
HHS unveiled the first phase of FDA's "Sentinel" post-market drug safety surveillance initiative with fanfare May 22, but stakeholders will have to wait a while for details on funding and the timing of a full-scale rollout
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.